---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Isatuximab-irfc - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/isatuximab-irfc
version: v1
---

# Isatuximab-irfc - NCI

# Isatuximab-irfc

Placeholder slot

(I-suh-TUK-sih-mab)

This page contains brief information about isatuximab-irfc
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Sarclisa

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0473462-6f9d-4eca-a5bf-8620aea68e8a)

## Use in Cancer

Isatuximab-irfc
is approved to treat:

- **[multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English).** It is used:
- with [pomalidomide](/Common/PopUps/popDefinition.aspx?id=589401&version=Patient&language=English) and [dexamethasone](/Common/PopUps/popDefinition.aspx?id=45262&version=Patient&language=English) in adults who have received at least two therapies, including [lenalidomide](/Common/PopUps/popDefinition.aspx?id=393761&version=Patient&language=English) and a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English)
- with [carfilzomib](/Common/PopUps/popDefinition.aspx?id=737706&version=Patient&language=English) and dexamethasone in
adults whose cancer has come back or did not respond to treatment with one to three other therapies
- with [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=Patient&language=English), lenalidomide, and dexamethasone in
adults with newly diagnosed cancer that cannot be treated with an
[autologous stem cell transplant](/Common/PopUps/popDefinition.aspx?id=270733&version=Patient&language=English)

Isatuximab-irfc
is also being studied in the treatment of other types of
cancer.

## More About Isatuximab-irfc

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/668181) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Isatuximab-irfc](https://medlineplus.gov/druginfo/meds/a620023.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[FDA Approvals Expand Initial Treatment Options for Multiple Myeloma](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Isatuximab-irfc](https://www.cancer.gov/research/participate/clinical-trials/intervention/C90578) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
